Advertisement
UK markets close in 1 hour 31 minutes
  • FTSE 100

    8,053.28
    +12.90 (+0.16%)
     
  • FTSE 250

    19,566.05
    -153.32 (-0.78%)
     
  • AIM

    752.44
    -2.25 (-0.30%)
     
  • GBP/EUR

    1.1654
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2471
    +0.0008 (+0.07%)
     
  • Bitcoin GBP

    50,726.10
    -2,151.11 (-4.07%)
     
  • CMC Crypto 200

    1,370.06
    -12.52 (-0.91%)
     
  • S&P 500

    4,999.38
    -72.25 (-1.42%)
     
  • DOW

    37,810.85
    -650.07 (-1.69%)
     
  • CRUDE OIL

    82.40
    -0.41 (-0.50%)
     
  • GOLD FUTURES

    2,332.80
    -5.60 (-0.24%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,847.16
    -241.54 (-1.34%)
     
  • CAC 40

    7,975.05
    -116.81 (-1.44%)
     

IBA – Transparency Notification

Louvain-la-Neuve, Belgium, September 2, 2020, 17.40

Summary of the notification

IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 2, 2020.

In its notification, Norges Bank has notified, that following a disposal of IBA shares with voting rights, its total holding in IBA SA has crossed downwards the 3% threshold.

In details, on August 27, 2020, Norges Bank owned (A) 1.110.771 IBA shares with voting rights (versus 1.147.133 shares in its previous notification), representing 2,90% of the total number of shares issued by IBA (38.254.807) (versus 3,00% in its previous notification), as well as (B) 22.337 equivalent financial instruments (versus 22.337 in its previous notification) representing 0,06% of the total number of shares issued by IBA (38.254.807) (versus 0,06% in its previous notification).

ADVERTISEMENT

Content of the notification

·Reason for the notification: Acquisition or disposal of voting securities or voting rights
·Persons subject to the notification requirement: Norges Bank
·Date on which the threshold is crossed: 27/08/2020
·Threshold crossed (in %): 3%
·Denominator: 38 254 807

·Notified details: (extract of the received notification form)

A) Voting rights

Previous notification

After the transaction

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

Linked to securities

Not linked to the securities

Linked to securities

Not linked to the securities

Norges Bank

1.147.133

1.110.771

2,90%

TOTAL

1.110.771

0

2,90%

0,00%

B) Equivalent financial instruments

After the transaction

Holder of equivalent financial instruments

Type of financial instrument

Expiration date

Exercise period or date

# of voting rights that may be acquired if the instrument is exercised

% of voting rights

Settlement

Norges Bank

Shares on loan (right to recall)

At any time

22.337

0,06%

physical

TOTAL

22.337

0,06%

TOTAL (A & B)

# of voting rights

%of voting rights

1.133.108

2,96%

·Full chain of controlled undertakings through which the holding is effectively held

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:

IBA

Elodie Jaumain
Paralegal
+32 10 203 180

legal@iba-group.com

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Attachment